

Rohit Aggarwal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1212150/rohit-aggarwal-publications-by-year.pdf>

Version: 2024-04-17

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

103
papers

4,310
citations

33
h-index

64
g-index

115
ext. papers

5,662
ext. citations

4.5
avg, IF

5.67
L-index

#	Paper	IF	Citations
103	COVID-19 vaccination outcomes among patients with dermatomyositis: a multicentered analysis.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	
102	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. <i>Indian Journal of Rheumatology</i> , 2022 ,	0.5	1
101	Systemic lupus erythematosus after Pfizer COVID-19 vaccine: a case report.. <i>Clinical Rheumatology</i> , 2022 , 1	3.9	0
100	Defining anti-synthetase syndrome: a systematic literature review.. <i>Clinical and Experimental Rheumatology</i> , 2022 , 40, 309-319	2.2	0
99	Telerheumatology and the Chronic Care Model 2022 , 209-226		
98	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. <i>Rheumatology International</i> , 2021 , 1	3.6	7
97	Validation of two simple patient-centered outcome measures for virtual monitoring of patients with idiopathic inflammatory myositis. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
96	Idiopathic inflammatory myopathies. <i>Nature Reviews Disease Primers</i> , 2021 , 7, 86	51.1	7
95	Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X211060907 ^{3.8}		0
94	Improving Pneumococcal Vaccination Rates in Rheumatology Patients by Using Best Practice Alerts in the Electronic Health Records. <i>Journal of Rheumatology</i> , 2021 , 48, 1472-1479	4.1	4
93	Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy. <i>Rheumatology</i> , 2021 , 60, 5713-5723	3.9	7
92	Utility of patient-reported outcomes measurement information system (PROMIS) physical function form in inflammatory myopathy. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 539-546	5.3	5
91	Hand-held dynamometry for assessment of muscle strength in patients with inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2146-2156	3.9	4
90	COVID-19 and myositis - unique challenges for patients. <i>Rheumatology</i> , 2021 , 60, 907-910	3.9	19
89	High Prevalence of Active Tuberculosis in Adults and Children with Idiopathic Inflammatory Myositis as Compared with Systemic Lupus Erythematosus in a Tuberculosis Endemic Country: Retrospective Data Review from a Tertiary Care Centre in India. <i>Mediterranean Journal of Rheumatology</i> , 2021 , 30, 104-110	1.4	0
88	Prospective, double-blind, randomized, placebo-controlled phase III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis ("ProDERM Study"). <i>Medicine (United States)</i> , 2021 , 100, e23677	1.8	10
87	Myositis-specific and myositis-associated autoantibodies in a large Indian cohort of inflammatory myositis. <i>Seminars in Arthritis and Rheumatism</i> , 2021 , 51, 113-120	5.3	12

86	A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2021 , 60, 2615-2628	3.9	12
85	COVID-19 and Myositis: What We Know So Far. <i>Current Rheumatology Reports</i> , 2021 , 23, 63	4.9	29
84	Consumer-based activity trackers in evaluation of physical activity in myositis patients. <i>Rheumatology</i> , 2021 ,	3.9	1
83	Follow-up results of myositis patients treated with H. P. Acthar gel. <i>Rheumatology</i> , 2020 , 59, 2976-2981	3.9	4
82	Risk Factors and Cancer Screening in Myositis. <i>Rheumatic Disease Clinics of North America</i> , 2020 , 46, 565-576	5.7	11
81	Clinical trials and novel therapeutics in dermatomyositis. <i>Expert Opinion on Emerging Drugs</i> , 2020 , 25, 213-228	3.7	3
80	Antisynthetase syndrome: A distinct disease spectrum.. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 178-191	2.3	7
79	Autoantibodies targeting TRIM72 compromise membrane repair and contribute to inflammatory myopathy. <i>Journal of Clinical Investigation</i> , 2020 , 130, 4440-4455	15.9	5
78	Evaluating the Patient with Suspected Myositis 2020 , 17-24		
77	Management Considerations: Pharmacologic Intervention 2020 , 275-283		1
76	Anti-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) antibody in necrotizing myopathy: treatment outcomes, cancer risk, and role of autoantibody level. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 405-411	1.9	9
75	Relationship between change in physical activity and in clinical status in patients with idiopathic inflammatory myopathy: A prospective cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2020 , 50, 1140-1149	5.3	5
74	Inclusion body myositis in the rheumatology clinic. <i>International Journal of Rheumatic Diseases</i> , 2020 , 23, 1126-1135	2.3	1
73	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020 , 182, 410-417	4	16
72	Treatment of calcinosis cutis in systemic sclerosis and dermatomyositis: A review of the literature. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 317-325	4.5	26
71	Refractory Cutaneous Dermatomyositis With Severe Scalp Pruritus Responsive to Apremilast. <i>Journal of Clinical Rheumatology</i> , 2019 ,	1.1	6
70	Tattoo reaction as a presenting manifestation of systemic sarcoidosis. <i>Rheumatology</i> , 2019 , 58, 927	3.9	5
69	Management of refractory cutaneous dermatomyositis: potential role of Janus kinase inhibition with tofacitinib. <i>Rheumatology</i> , 2019 , 58, 1011-1015	3.9	45

68	Response to: Q Elephant in the room Q by Hartung. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, e12	2.4	
67	Drs. Aggarwal and Oddis reply. <i>Journal of Rheumatology</i> , 2018 , 45, 446	4.1	1
66	Rituximab in the Treatment of Interstitial Lung Disease Associated with Antisynthetase Syndrome: A Multicenter Retrospective Case Review. <i>Journal of Rheumatology</i> , 2018 , 45, 841-850	4.1	55
65	Update on outcome assessment in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 303-318	8.1	55
64	The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 48, 504-512	5.3	19
63	Treatment in myositis. <i>Nature Reviews Rheumatology</i> , 2018 , 14, 279-289	8.1	54
62	Pulmonary Pathologic Manifestations of Anti-Alanyl-tRNA Synthetase (Anti-PL-12)-Related Inflammatory Myopathy. <i>Archives of Pathology and Laboratory Medicine</i> , 2018 , 142, 191-197	5	4
61	Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 55-62	2.4	61
60	Efficacy and safety of adrenocorticotrophic hormone gel in refractory dermatomyositis and polymyositis. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 720-727	2.4	30
59	Myositis in clinical practice-relevance of new antibodies. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 887-901	5.3	2
58	Anti-MDA5 Antibody Spectrum in Western World. <i>Current Rheumatology Reports</i> , 2018 , 20, 78	4.9	22
57	Modern Therapies for Idiopathic Inflammatory Myopathies (IIMs): Role of Biologics. <i>Clinical Reviews in Allergy and Immunology</i> , 2017 , 52, 81-87	12.3	12
56	Myositis-associated usual interstitial pneumonia has a better survival than idiopathic pulmonary fibrosis. <i>Rheumatology</i> , 2017 , 56, 384-389	3.9	11
55	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. <i>Journal of Rheumatology</i> , 2017 , 44, 319-325	4.1	68
54	A Negative Antinuclear Antibody Does Not Indicate Autoantibody Negativity in Myositis: Role of Anticytoplasmic Antibody as a Screening Test for Antisynthetase Syndrome. <i>Journal of Rheumatology</i> , 2017 , 44, 223-229	4.1	43
53	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 59, 898-910	9.5	36
52	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Arthritis and Rheumatology</i> , 2017 , 59, 898-910	9.5	33
51	2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 792-801	2.4	65

50	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 782-791	2.4	24
49	2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1955-1964	2.4	393
48	Drs. Sheth and Aggarwal reply. <i>Journal of Rheumatology</i> , 2017 , 44, 961	4.1	
47	Drs. Aggarwal and Oddis reply. <i>Journal of Rheumatology</i> , 2017 , 44, 1565	4.1	
46	Biologics for idiopathic inflammatory myopathies. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 645-651	5.3	5
45	EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. <i>RMD Open</i> , 2017 , 3, e000507	5.9	66
44	2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2271-2282	9.5	210
43	Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. <i>Rheumatology</i> , 2017 , 56, 247-254	3.9	51
42	Improvement in Herpes Zoster Vaccination in Patients with Rheumatoid Arthritis: A Quality Improvement Project. <i>Journal of Rheumatology</i> , 2017 , 44, 11-17	4.1	16
41	2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects. <i>Rheumatology</i> , 2017 , 56, 1884-1893	3.9	23
40	Anti-Melanoma Differentiation-Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. <i>Arthritis Care and Research</i> , 2016 , 68, 689-94	4.7	134
39	Immune-mediated statin myopathy. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 33-8	5.1	14
38	Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab. <i>Rheumatology</i> , 2016 , 55, 991-9	3.9	45
37	Approach to asymptomatic creatine kinase elevation. <i>Cleveland Clinic Journal of Medicine</i> , 2016 , 83, 37-42.8		74
36	Repository Corticotropin Injection for Treatment of Idiopathic Inflammatory Myopathies. <i>Case Reports in Rheumatology</i> , 2016 , 2016, 9068061	0.8	11
35	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) - Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015 , 42, 2168-71	4.1	99
34	The pulmonary histopathology of anti-KS transfer RNA synthetase syndrome. <i>Archives of Pathology and Laboratory Medicine</i> , 2015 , 139, 122-5	5	14
33	Distinctions between diagnostic and classification criteria?. <i>Arthritis Care and Research</i> , 2015 , 67, 891-7	4.7	268

32	Anti-signal recognition particle autoantibody ELISA validation and clinical associations. <i>Rheumatology</i> , 2015 , 54, 1194-9	3.9	26
31	Treatment of inflammatory myopathy: emerging therapies and therapeutic targets. <i>Expert Review of Clinical Immunology</i> , 2015 , 11, 1265-75	5.1	20
30	Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients. <i>International Journal of Rheumatic Diseases</i> , 2015 , 18, 646-53	2.3	9
29	Histopathologic Findings in 5 Patients With Hypomyopathic Dermatomyositis: The Importance of MHC-1 Expression on Myofibers. <i>Journal of Clinical Neuromuscular Disease</i> , 2015 , 17, 52-8	1.1	3
28	Biologic predictors of clinical improvement in rituximab-treated refractory myositis. <i>BMC Musculoskeletal Disorders</i> , 2015 , 16, 257	2.8	31
27	Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab. <i>Clinical and Experimental Rheumatology</i> , 2015 , 33, 655-63	2.2	9
26	Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation. <i>Rheumatology</i> , 2014 , 53, 433-7	3.9	12
25	Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 227-32	2.4	172
24	Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. <i>Arthritis and Rheumatology</i> , 2014 , 66, 740-9	9.5	167
23	Update on the treatment of myositis. <i>International Journal of Clinical Rheumatology</i> , 2014 , 9, 505-518	1.5	1
22	The use and abuse of diagnostic/classification criteria. <i>Best Practice and Research in Clinical Rheumatology</i> , 2014 , 28, 921-34	5.3	31
21	Pulmonary pathologic manifestations of anti-glycyl-tRNA synthetase (anti-EJ)-related inflammatory myopathy. <i>Journal of Clinical Pathology</i> , 2014 , 67, 678-83	3.9	23
20	The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. <i>Human Pathology</i> , 2014 , 45, 1199-204	3.7	19
19	B-Cell Targeted Therapies in Systemic Sclerosis and Inflammatory Myopathies. <i>Milestones in Drug Therapy</i> , 2014 , 153-180		1
18	Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. <i>Arthritis and Rheumatism</i> , 2013 , 65, 314-24		383
17	Perioperative Management of the Patient with Idiopathic Inflammatory Myopathy 2013 , 201-208		
16	Therapeutic advances in myositis. <i>Current Opinion in Rheumatology</i> , 2012 , 24, 635-41	5.3	38
15	Inclusion body myositis: therapeutic approaches. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2012 , 2, 43-52	5.4	4

14	Paraneoplastic myalgias and myositis. <i>Rheumatic Disease Clinics of North America</i> , 2011 , 37, 607-21	2.4	28
13	Methods of formal consensus in classification/diagnostic criteria and guideline development. <i>Seminars in Arthritis and Rheumatism</i> , 2011 , 41, 95-105	5.3	204
12	Therapeutic approaches in myositis. <i>Current Rheumatology Reports</i> , 2011 , 13, 182-91	4.9	17
11	Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. <i>Arthritis Care and Research</i> , 2011 , 63, 891-8	4.7	52
10	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2582-91		182
9	Psychometric properties of the EuroQol-5D and Short Form-6D in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2009 , 36, 1209-16	4.1	60
8	Safety of etanercept in patients at high risk for mycobacterial tuberculosis infections. <i>Journal of Rheumatology</i> , 2009 , 36, 914-7	4.1	23
7	Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. <i>Journal of Rheumatology</i> , 2009 , 36, 2711-4	4.1	54
6	Anti-U3 RNP autoantibodies in systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009 , 60, 1112-8		102
5	Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1472-83		133
4	Diagnosis delay in patients with ankylosing spondylitis: factors and outcomes--an Indian perspective. <i>Clinical Rheumatology</i> , 2009 , 28, 327-31	3.9	56
3	Clinical characteristics of patients with ankylosing spondylitis in India. <i>Clinical Rheumatology</i> , 2009 , 28, 1199-205	3.9	43
2	Chemokines in multiple myeloma. <i>Experimental Hematology</i> , 2006 , 34, 1289-95	3.1	110
1	Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review. <i>Rheumatology International</i> ,	3.6	0